Recent News

• 03.25.2025 - AN2 Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business and Scientific Highlights
• 03.25.2025 - AN2 Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business and Scientific Highlights
• 03.12.2025 - Leerink's Global Healthcare Conference 2025
• 03.12.2025 - Leerink's Global Healthcare Conference 2025
• 03.03.2025 - AN2 Therapeutics to Present at Leerink Partners Global Healthcare Conference
• 03.03.2025 - AN2 Therapeutics to Present at Leerink Partners Global Healthcare Conference
• 03.03.2025 - TD Cowen 45th Annual Health Care Conference
• 03.03.2025 - TD Cowen 45th Annual Health Care Conference
• 02.24.2025 - AN2 Provides Strategic Update for Phase 3 EBO-301 Trial in Treatment Refractory MAC Lung Disease
• 02.24.2025 - AN2 Provides Strategic Update for Phase 3 EBO-301 Trial in Treatment Refractory MAC Lung Disease

Recent Filings

• 02.28.2025 - 4 Statement of changes in beneficial ownership of securities
• 02.28.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 02.28.2025 - 4 Statement of changes in beneficial ownership of securities
• 02.28.2025 - 4 Statement of changes in beneficial ownership of securities
• 02.28.2025 - 4 Statement of changes in beneficial ownership of securities
• 02.28.2025 - 4 Statement of changes in beneficial ownership of securities
• 02.14.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors